In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.

Exploring Analyst...